UPDATE: Goldman Sachs Upgrades Humana from Neutral to Buy

Goldman Sachs has published a report upgrading Humana (NYSE: HUM) from Neutral to Buy.

In the report, Goldman Sachs wrote, "We think fiscal pressures will drive a bigger role for Medicare Advantage (MA) and ultimately a phasing-out of unmanaged ‘traditional' Medicare. Even without policy changes, MA is becoming the product choice for seniors as employer retiree coverage becomes increasing rare."

Goldman Sachs upgraded Humana from Neutral to Buy with a price target of $91.00. Humana closed Tuesday at $65.65.